OCUL
Ocular Therapeutix Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Market Cap: 860 Million
Primary Exchange: NASDAQ
Website: http://www.ocutx.com/
Shares Outstanding: 79.4 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.903395966602386
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2383 trading days
From: 2015-03-24 To: 2024-03-07
Lowest Point:
Ocular Therapeutix: Launch Looms, Insiders Buying
via: SeekingAlpha at 2019-06-10 09:15:07:000
Shares of Ocular Therapeutix ( OCUL ) have lost nearly three-quarters of their value since IPO was priced at $13 in 2014. Over the past year, the stock has lost half its value and is in the red by roughly 15% so far in 2019. This busted IPO popped up on my radar after a recent cluster of in… read more...
Ocular Therapeutix: Launch Looms, Insiders Buying
via: SeekingAlpha at 2019-06-10 09:15:07:000
Shares of Ocular Therapeutix ( OCUL ) have lost nearly three-quarters of their value since IPO was priced at $13 in 2014. Over the past year, the stock has lost half its value and is in the red by roughly 15% so far in 2019. This busted IPO popped up on my radar after a recent cluster of in… read more...
Ocular Therapeutix: Launch Looms, Insiders Buying
via: SeekingAlpha at 2019-06-10 09:15:07:000
Shares of Ocular Therapeutix ( OCUL ) have lost nearly three-quarters of their value since IPO was priced at $13 in 2014. Over the past year, the stock has lost half its value and is in the red by roughly 15% so far in 2019. This busted IPO popped up on my radar after a recent cluster of in… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|